The first drug that has been approved in the United States to lower proprotein convertase subtilisin Kexin 9 (PCSK-9) is:
A) gemfibrozil (Lopid®)
B) simvastatin/ezetimibe (Vytorin®)
C) nicotinic acid (Niacor®)
D) alirocumab (Praluent®)
D) alirocumab (Praluent®)
The first drug approved in the United States to lower proprotein convertase subtilisin Kexin 9 (PCSK-9) is alirocumab (Praluent®). The gene, PCSK-9, is important for plasma cholesterol metabolism. Alirocumab is administered by injection, and is indicated for familial hypercholesterolemia, or for patients with a history of heart disease in whom statins are not sufficiently effective.
You might also like to view...
Morbid obesity is defined as a BMI over what value?
a. 20 kg/m2 b. 25 kg/m2 c. 30 kg/m2 d. 35 kg/m2
Which of the following is NOT a type of taste bud?
A. Chewy B. Sweet C. Salty D. Sour
At what point in a breath hold deep dive would the CO2-O2 paradox occur?
A. CO2 paradox occurs on descent, O2 paradox occurs on ascent. B. O2 paradox occurs on descent, CO2 paradox occurs on ascent C. both occur during descent D. both occur during ascent
A genetically inherited disorder in which the body cannot properly metabolize the nutrient phenylalanine, resulting in mental retardation, is ________.
A. phenylketonuria B. bilirubinuria C. glycosuria D. hemoglobinuria E. myoglobinuria